Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Hahn on Patient Selection for Abiraterone Versus Docetaxel in mHSPC

May 31st 2018

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses patient selection for abiraterone acetate (Zytiga) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Choyke on the Importance of Multidisciplinary Care in Prostate Cancer

May 30th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute (NCI), discusses the importance of multidisciplinary care in prostate cancer.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

Dr. Godwin on Immunotherapy Efforts in Prostate Cancer

May 24th 2018

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses immunotherapy efforts in prostate cancer.

FDA Approves New Abiraterone Acetate Formulation for mCRPC

May 24th 2018

The FDA has approved a new formulation of abiraterone acetate in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer.

Dr. Trabulsi Discusses Postoperative Radiation in Prostate Cancer

May 23rd 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.

Apalutamide Reduces Risk of PSA Progression by 94% in Nonmetastatic CRPC

May 21st 2018

Apalutamide (Erleada) lowered the risk of PSA progression by 94% in patients with nonmetastatic castration-resistant prostate cancer, according to a posthoc analysis from the phase III SPARTAN trial.

ADT and Cardiovascular Risk in Prostate Cancer: Q&A

May 21st 2018

Strategies for Preventing CV Events in Prostate Cancer

May 21st 2018

Managing Metabolic Aberrations and CV Events from ADT

May 21st 2018

Predicting Risk for Metabolic Aberrations and CV Events

May 21st 2018

Metabolic Aberrations Associated With ADT

May 21st 2018

Likelihood for Cardiovascular Events After ADT

May 21st 2018

Androgens and Cardiovascular Events

May 21st 2018

Cardio-Oncology in Prostate Cancer

May 21st 2018

Reducing the Risk for Cardiovascular Events: PRONOUNCE

May 21st 2018

Significance of GnRH Antagonists in Prostate Cancer

May 21st 2018

Challenges Associated with ADT in Prostate Cancer

May 21st 2018

Burden of Cardiovascular Disease in Prostate Cancer

May 21st 2018

ADT as Treatment in Metastatic Prostate Cancer

May 21st 2018